Current issues related to management of advanced prostate cacner in Europe

According to an article on PharmaTimes Online, a new report issued in Europe suggests that "European healthcare systems are failing to deliver the latest medical breakthroughs to men with advanced prostate cancer."

The report, entitled “Every month matters: improving advanced prostate cancer care in Europe,” was developed either by or with funding from Astellas Pharma (which markets the new drug enzalutamide, also known as Xtandi). However, it does not promote any specific pharmaceutical product and it does provide useful information about the diagnosis and management of advanced and metastatic prostate cancer in many European nations.

Copies of the full report and related information can be downloaded if you click here.

3 Responses


    Thanks for posting this report. It should go a long way toward helping those of us in the US understand the situation in Europe, which I take to include the UK, despite John Cleese’s displeasure. I am starting to read the 42-page report, and I noticed this statement at the beginning of the executive summary.

    “Once metastases have developed, prostate cancer is advanced and incurable.”

    While still controversial, perhaps, the view is evolving that “oligometastatic” prostate cancer, with “oligometastatic” meaning few, and specifically implying 5 bone metastases or fewer as a key dividing line between what may be treatable with curative intent and what may not, can sometimes be treated effectively with radiation specially targeted to wipe out each metastasis. This is now being done for men with bone metastases, with lymph node metastases, and with both. As the advanced imaging technology and targeted radiation and surgery techniques are still evolving, my impression is that the jury is still out regarding reliable results.

  2. I think there are several issues that are still not clear when it comes to prostate cancer not only in Europe but around the world. According to what I’ve read, about 90% of males around the world are prone to prostate cancer when they reach ages of 60 and above.

  3. Dear Strong and Beautiful:

    Well … 90% is probably an excessive claim. However, it is certainly the case that if one carries out pathological examinations of the prostate as a component of the autopsies of men who died from other causes, and who had no clinical evidence of prostate cancer, one will find that about 60 percent of men in their 60s have some amount of prostate cancer.

    On the other hand, most of these men will not have any indication of clinically significant prostate cancer. In other words, if they were never diagnosed they would never know they had prostate cancer in their lifetimes and would die of some other disorder. It is for this and related reasons that we worry about over-treatment of men with clinically insignificant disease.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: